Pain and sedation — Revenue
Zoetis Pain and sedation — Revenue decreased by 2.9% to $203.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.3%, from $210.00M to $203.00M. Over 3 years (FY 2022 to FY 2025), Pain and sedation — Revenue shows an upward trend with a 26.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests strong market adoption of the company's therapeutic portfolio and successful penetration into veterinary clinics, while a decrease may indicate increased competition or a shift in veterinary prescribing patterns.
Detailed definition
This metric represents the total revenue generated from the sale of pharmaceutical products specifically designed for pa...
Peer comparison
Peers in the animal health sector report similar revenue streams under therapeutic categories like 'Pain, Sedation, and Anesthesia' or 'Specialty Pharmaceuticals'.
zts_segment_pain_and_sedation_revenueHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $105.00M | $105.00M | $105.00M | $105.00M | $116.00M | $145.00M | $147.00M | $194.00M | $194.00M | $221.00M | $219.00M | $217.00M | $210.00M | $217.00M | $204.00M | $209.00M | $203.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +10.5% | +25.0% | +1.4% | +32.0% | +0.0% | +13.9% | -0.9% | -0.9% | -3.2% | +3.3% | -6.0% | +2.5% | -2.9% |
| YoY Change | — | — | — | — | +10.5% | +38.1% | +40.0% | +84.8% | +67.2% | +52.4% | +49.0% | +11.9% | +8.2% | -1.8% | -6.8% | -3.7% | -3.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Zoetis's pain and sedation — revenue?
- Zoetis (ZTS) reported pain and sedation — revenue of $203.00M in Q1 2026.
- How has Zoetis's pain and sedation — revenue changed year-over-year?
- Zoetis's pain and sedation — revenue decreased by 3.3% year-over-year, from $210.00M to $203.00M.
- What is the long-term trend for Zoetis's pain and sedation — revenue?
- Over 3 years (2022 to 2025), Zoetis's pain and sedation — revenue has grown at a 26.0% compound annual growth rate (CAGR), from $420.00M to $840.00M.
- What does pain and sedation — revenue mean?
- Total revenue earned from selling animal pain relief and sedative medications.